Short answer: no peptide has been proven to fix sleep in humans. The compounds people search for — DSIP, Epithalon, Ipamorelin, Sermorelin, CJC-1295, Selank, BPC-157 — fall into three groups: one that was tested for sleep and mostly failed, several that borrow their reputation from studies of a different molecule, and a few with no sleep data at all. This page sorts them, shows what each study actually measured, and says plainly where the evidence stops.
Research-use-only educational overview. None of these compounds is an approved treatment for insomnia or any sleep disorder anywhere in the world, and nothing here is medical advice or a recommendation to use any of them.
Every “sleep peptide,” ranked by evidence
| Peptide | What was actually measured | Evidence tier for sleep | Honest verdict |
|---|---|---|---|
| DSIP (Delta Sleep-Inducing Peptide) | Sleep itself — EEG sleep stages in animals and small human groups | Preclinical + small, dated human trials | The only one tested directly for sleep. The best-controlled trial in insomniacs was negative. |
| Ghrelin (the natural hormone) | Slow-wave sleep, by polysomnography, in healthy volunteers | Small randomised human trials — positive, but only in men, only at night | Real human sleep data — for the hormone, not for the peptides sold online. |
| Ipamorelin, GHRP-2, GHRP-6 | Growth hormone release. No published sleep-outcome study. | Mechanistic inference only | Ghrelin-receptor agonists. The sleep claim is borrowed from ghrelin, not tested on them. |
| Sermorelin, CJC-1295, tesamorelin | Growth hormone release. No published sleep-outcome study. | Mechanistic inference only | GHRH analogues. GHRH itself increases slow-wave sleep; these analogues were never tested for it. |
| Epithalon (Epitalon / AEDG) | Melatonin levels and rhythm — not sleep | Preclinical + small human biomarker studies | Plausible circadian rationale, but no trial has measured whether people sleep better. |
| Selank | Anxiety scores; sleep appears only as a side-effect measure | Small Russian clinical trials, anxiety endpoints | Studied for anxiety, not for sleep. Any sleep benefit is second-hand at best. |
| Pinealon (EDR) | Neuroprotection, antioxidant activity, cognition | Preclinical only | No sleep study exists. Its “sleep peptide” label comes from the pineal name alone. |
| BPC-157 | Tissue repair in rodents | Preclinical, unrelated endpoints | Appears on sleep lists with no sleep research behind it at all. |
A useful baseline before the detail: a search of ClinicalTrials.gov returns no registered clinical trial testing DSIP, Epithalon or Pinealon for sleep, and a 2026 review that groups them together as circadian-acting “recovery” peptides states outright that there is “a current lack of clinical trials” (Rahman et al., 2026).
DSIP — the only one actually tested for sleep
DSIP was isolated in the 1970s and named for promoting delta (slow-wave) sleep when infused into rabbits, rats and cats (Graf & Kastin, 1984; Susić et al., 1987). An early human crossover study in six volunteers reported total sleep time rising about 59 % in a short interval after infusion (Schneider-Helmert et al., 1981, PMID 6895513).
Then came the test that matters. A double-blind randomised trial in 16 chronic insomniacs — the only controlled study in the population that actually has a sleep problem — found the effects “weak” and concluded that short-term DSIP was “not likely to be of major therapeutic benefit” (Bes et al., 1992). A later review described the DSIP–sleep link as “extremely poorly documented and still weak” (Kovalzon & Strekalova, 2006).
So DSIP is the most-studied sleep peptide and the one with the clearest negative result. Both things are true. Handling and reconstitution documentation is on the DSIP 5 mg vial protocol page.
Ipamorelin, GHRP-2, Sermorelin, CJC-1295 — borrowed evidence
This is the group most people are really asking about, and it is the one where marketing and research diverge hardest.
What is genuinely documented: ghrelin, the body’s own growth-hormone secretagogue, increases slow-wave sleep in humans. In seven healthy men given four 50 µg intravenous boluses between 22:00 and 01:00, slow-wave sleep rose across the whole night and delta activity increased in the second half; REM fell (Weikel et al., 2003, DOI). The same group replicated it in ten elderly men, where slow-wave sleep went from 33.4 to 44.3 minutes and non-REM sleep from 273 to 318 minutes (Kluge et al., 2009). Growth-hormone-releasing hormone (GHRH) does something similar (Kluge et al., 2007). According to PubMed, that is the real basis for the whole “GH peptides deepen your sleep” story.
What that evidence does not cover:
- Sex. The identical protocol in ten healthy young women produced no change in any sleep variable, conventional or quantitative — while still raising GH and cortisol normally (Kluge et al., 2007). The sleep effect appears to be male-specific in these studies.
- Timing. Give the same ghrelin doses at 04:00–07:00 instead and sleep does not change at all, even though GH and cortisol still spike (Kluge et al., 2007). The hormone response and the sleep response are not the same thing.
- The molecules themselves. A PubMed search for ipamorelin combined with sleep or polysomnography returns zero results. The same is true for CJC-1295. Ipamorelin and GHRP-2 are synthetic ghrelin-receptor agonists and sermorelin, CJC-1295 and tesamorelin are GHRH analogues — a reasonable mechanistic argument, but nobody has run the sleep study.
- Insomnia. Every trial above used healthy volunteers in a sleep lab. None enrolled people with a sleep complaint.
In short: the receptor is right, the hormone data are real, and the leap from “IV ghrelin raised slow-wave sleep in seven men” to “this peptide will fix your sleep” has never been tested. Compound references: Ipamorelin 5 mg, GHRP-2 5 mg, Sermorelin 5 mg, CJC-1295 DAC 5 mg.
Epithalon — a melatonin argument, not a sleep result
Epithalon is a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly). Its link to sleep is indirect: it is studied as a modulator of the pineal gland and of melatonin, the hormone that sets sleep–wake timing. In aged animals and small groups of elderly people with reduced pineal function, Epithalon and the related extract Epithalamin have been reported to raise nighttime melatonin and help normalise its rhythm (Korkushko et al., 2007, PMID 17969590; Khavinson, 2002, PMID 12374906). A 2025 review confirms Epithalon can influence melatonin synthesis but stresses that the mechanisms “remain uncertain” and that most data are in vitro or in animals (Araj et al., 2025).
Read that carefully: these are melatonin-marker studies, not sleep-outcome trials. They come largely from one research lineage, and none of them reports whether participants slept longer or better. Handling reference: Epithalon 10 mg vial protocol page.
Selank — an anxiety peptide on a sleep list
Selank is a synthetic analogue of tuftsin studied in Russia as an anxiolytic. In a randomised trial adding Selank to phenazepam in 40 patients with anxiety disorders, the combination reached its positive effect earlier on the Hamilton rating scale and reduced the tranquilliser’s side-effect burden — and the side effects it reduced included sedation and increased sleep duration (Medvedev et al., 2015). Sleep appears in that study as a benzodiazepine side effect being lessened, not as a benefit being produced.
If poor sleep is driven by anxiety, an anxiolytic is a coherent thing to study. But no trial has measured Selank against a sleep endpoint, and the published work is limited to a small number of Russian-language studies. Reference: Selank 5 mg vial protocol page.
Pinealon and BPC-157 — no sleep research at all
Despite a name that evokes the pineal gland, Pinealon research is about neuroprotection, antioxidant activity and cognition. It reduces reactive-oxygen-species damage in nerve-cell cultures (Khavinson et al., 2011) and is discussed for gene-expression effects in Alzheimer’s models (Khavinson et al., 2020). We identified no human or animal study measuring a sleep outcome for it. See the Pinealon 20 mg vial protocol page.
BPC-157 turns up on “best peptides for sleep” lists for the same reason: name recognition. Its research base is rodent tissue repair (BPC-157 5 mg vial protocol page), with no sleep endpoint anywhere in it.
How much, and when — the amounts the sleep studies actually used
Search results are full of “sleep peptide dosages.” Almost none of them come from the studies they cite. Here is every published human sleep experiment on this page, with what was actually given.
| Compound | Study & participants | Amount given | Route and timing | What happened |
|---|---|---|---|---|
| DSIP | Schneider-Helmert et al., 1981 — 6 healthy volunteers (PMID 6895513) | 25 nmol/kg | Slow intravenous infusion, in the morning | Total sleep time up about 59 % in the 130 minutes after the infusion; shorter sleep onset the following night |
| DSIP | Bes et al., 1992 — 16 chronic insomniacs (DOI) | 25 nmol/kg | Intravenous, in the afternoon before each of 3 consecutive nights | Sleep efficiency and latency improved slightly, but the authors called the effects weak and concluded short-term DSIP is “not likely to be of major therapeutic benefit” |
| Ghrelin | Weikel et al., 2003 — 7 healthy young men (DOI) | 4 × 50 µg | Intravenous boluses, hourly between 22:00 and 01:00 | Slow-wave sleep increased across the night; delta activity rose in the second half; REM fell |
| Ghrelin | Kluge et al., 2009 — 10 elderly men and 10 elderly women (DOI) | 50 µg × 4 | Intravenous boluses at 22:00, 23:00, 00:00 and 01:00 | In the men, slow-wave sleep 33.4 → 44.3 minutes and non-REM sleep 272.6 → 318.2 minutes. In the women, no effect. |
| Ghrelin | Kluge et al., 2007 — 10 healthy young women (DOI) | 50 µg × 4 | Intravenous boluses at 22:00, 23:00, 00:00 and 01:00 — the same protocol as the men | No change in any sleep variable, although growth hormone and cortisol still rose normally |
| Ghrelin | Kluge et al., 2007 — 12 healthy young men (DOI) | 50 µg × 4 | Intravenous boluses at 04:00, 05:00, 06:00 and 07:00 instead of late evening | No change in any sleep variable, although growth hormone and cortisol still rose |
Three things follow from that table, and they are the reason no honest dosing chart for sleep peptides exists.
- Every one of these was intravenous, in a sleep laboratory. Infusions and timed boluses given by a clinician are not the same exposure as a subcutaneous injection drawn from a reconstituted vial. Nothing in this literature establishes a subcutaneous amount for sleep.
- The two compounds with human sleep data are not the ones being sold. DSIP is, but its controlled insomnia trial was negative. Ghrelin is a natural hormone tested intravenously — not Ipamorelin, not GHRP-2, not Sermorelin, not CJC-1295.
- Timing changed the result more than the amount did. The same four 50 µg boluses raised slow-wave sleep when given between 22:00 and 01:00 to men, and did nothing when given between 04:00 and 07:00, or to women of any age. A number without a time of night, a sex and a route is not a finding.
For Epithalon, Selank and Pinealon there is no row to add here: no published study has measured a sleep outcome at any amount. Vial reconstitution arithmetic for laboratory documentation is on each compound’s protocol page — for example DSIP 5 mg and Epithalon 10 mg — and describes how a vial is prepared, not a sleep dose that anyone has validated.
What does have sleep evidence
This page is about research peptides, so it is worth stating plainly what sits on the other side of the evidence line — because that is the comparison every one of these compounds is implicitly asking you to make.
- Cognitive behavioural therapy for insomnia (CBT-I). The American College of Physicians recommends CBT-I as the initial treatment for chronic insomnia in all adults, graded a strong recommendation on moderate-quality evidence (Qaseem et al., 2016). No peptide on this page has anything approaching that evidence base.
- Treating the underlying cause. Persistent insomnia is often driven by sleep apnoea, restless legs, a medication, pain, or an anxiety or mood disorder. Those are diagnosable, and treating them is what changes sleep.
- Melatonin, within its limits. Melatonin has been through many controlled trials; the honest summary is that its effects are modest and mainly concern sleep timing and onset rather than sleep depth. It is still far better characterised than Epithalon, which is studied for its effect on the body’s own melatonin rhythm and has never been tested against a sleep endpoint.
None of that is a recommendation about anyone’s own sleep — it is where the published evidence is concentrated. A clinician is the right place to start with a persistent sleep problem.
What to expect — and how long it would take to know
Because no product here has a validated sleep protocol, there is no honest “results in X days” figure to give. What the research design itself tells you is worth knowing:
- The measured effects were same-night. Ghrelin changed sleep architecture during the infusion night, not after a fortnight of accumulation. Any claim built on a “loading phase” is not coming from these studies.
- The effects were modest. Roughly eleven extra minutes of slow-wave sleep in the elderly-men study — a real EEG change, not a transformation of how someone feels.
- Feeling different is not the same as sleeping better. GH secretagogues raise cortisol as well as GH. Subjective grogginess, vividness of dreams or early waking are not evidence a peptide worked.
- Half of the trials showed nothing. Wrong sex, wrong time of night, and the effect disappeared. That is a fragile signal, not a reliable one.
Safety: what is known and what is not
- No long-term human safety data exist for DSIP, Epithalon, Pinealon or Selank. The human studies that exist are small, short and often decades old.
- The GH secretagogues raise cortisol and prolactin alongside growth hormone (Weikel et al., 2003), and ghrelin-receptor agonists such as GHRP-2 also stimulate appetite. Those are documented endocrine effects, not hypothetical ones.
- Product quality is an unquantified variable. These are unregulated research chemicals; purity, identity and labelling vary between sellers, which means adverse events cannot cleanly be attributed to the peptide itself.
- Persistent insomnia often has a treatable cause — sleep apnoea, restless legs, a medication, an anxiety or mood disorder. Cognitive behavioural therapy for insomnia (CBT-I) is the treatment the American College of Physicians recommends first for every adult with chronic insomnia (Qaseem et al., 2016), and it is the intervention with the evidence base none of these peptides has. A qualified clinician is the right starting point, not a vial.
FAQ
What is the best peptide for sleep?
There is no best one, because none has been shown to work. DSIP has the most direct human sleep data and its best-controlled trial was negative (Bes et al., 1992). Ghrelin has the strongest positive human sleep data, but ghrelin itself is not what is sold as a research peptide.
Does Ipamorelin improve deep sleep?
No study has measured it. A PubMed search for ipamorelin with sleep or polysomnography returns nothing. The claim comes from studies of ghrelin, the natural hormone Ipamorelin mimics at the GHS-R1a receptor — and even that effect was absent in women and absent when the dose was given in the early morning (Kluge et al., 2007).
Is Sermorelin or CJC-1295 better for sleep than Ipamorelin?
Nobody knows, because neither has been compared for sleep — or tested for it. Sermorelin and CJC-1295 are GHRH analogues and Ipamorelin is a ghrelin-receptor agonist; both parent hormones increase slow-wave sleep in humans, but that is a statement about GHRH and ghrelin, not about the analogues.
What DSIP dosage was used in the sleep studies?
Both published human trials used 25 nmol/kg of body weight, given intravenously in a sleep laboratory — as a morning infusion in six healthy volunteers (PMID 6895513) and in the afternoon before three consecutive nights in 16 chronic insomniacs (Bes et al., 1992). No published trial has established a subcutaneous amount, and the insomnia trial — the one in people who actually had a sleep problem — was negative.
How long do sleep peptides take to work?
The only human trials that changed sleep did so on the night of administration. Since no analogue sold as a research peptide has a completed sleep trial, any specific timeline you see quoted — two weeks, one cycle, thirty days — is not coming from published data.
Are peptides for sleep safe?
Unknown. None is approved for sleep, none has long-term human safety data, and the GH secretagogues measurably raise cortisol and prolactin as well as growth hormone. Absence of reported harm in small short trials is not the same as established safety.
Is Epithalon just an expensive way of taking melatonin?
No — but it has less evidence. Epithalon is studied for its effect on the pineal gland’s own melatonin production and rhythm, mostly in aged animals and small elderly cohorts (Korkushko et al., 2007, PMID 17969590). Supplemental melatonin, by contrast, has been through many controlled sleep trials. Epithalon has been through none.
Which sleep peptide has actual human trials?
Only DSIP, and only a handful of small ones from the 1980s and early 1990s. Ghrelin has modern randomised polysomnography data, but it is a hormone studied intravenously in a sleep laboratory, not a product.
Limitations of this overview
- Evidence tiers matter. Much of what circulates about these peptides is preclinical or anecdotal; animal and cell-culture findings are not proof of a human sleep benefit.
- Absence of a study is not proof a compound does nothing — it means nobody has checked, which is its own risk.
- Sources here are drawn from PubMed and ClinicalTrials.gov and were current at the time of writing.
Researchers working through reconstitution and concentration arithmetic for laboratory documentation can use the peptide dosage calculator. It is a computational reference tool, not a recommendation to administer anything.
References
- Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981;19(8):341–345. PMID 6895513
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193–197. doi:10.1159/000118919
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984. doi:10.1016/0149-7634(84)90022-8
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006. doi:10.1111/j.1471-4159.2006.03693.x
- Weikel JC, Wichniak A, Ising M, et al. Ghrelin promotes slow-wave sleep in humans. Am J Physiol Endocrinol Metab. 2003. doi:10.1152/ajpendo.00184.2002
- Kluge M, Schüssler P, Zuber V, Yassouridis A, Steiger A. Ghrelin administered in the early morning increases secretion of cortisol and growth hormone without affecting sleep. Psychoneuroendocrinology. 2007;32(3):287–292. doi:10.1016/j.psyneuen.2006.12.015
- Kluge M, Schüssler P, Zuber V, et al. Ghrelin enhances the nocturnal secretion of cortisol and growth hormone in young females without influencing sleep. Psychoneuroendocrinology. 2007;32(8–10):1079–1085. doi:10.1016/j.psyneuen.2007.09.001
- Kluge M, Gazea M, Schüssler P, et al. Ghrelin increases slow wave sleep and stage 2 sleep and decreases stage 1 sleep and REM sleep in elderly men but does not affect sleep in elderly women. Psychoneuroendocrinology. 2009;35(2):297–304. doi:10.1016/j.psyneuen.2009.07.007
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people. 2007. PMID 17969590
- Khavinson VKh. Peptides and ageing. 2002. PMID 12374906
- Araj S, et al. Epithalon and the pineal gland: a review. Int J Mol Sci. 2025. doi:10.3390/ijms26062691
- Medvedev VE, et al. Efficacy and safety of Selank in the treatment of anxiety disorders. 2015. doi:10.17116/jnevro20151156133-40
- Khavinson VKh, et al. Peptide regulation of gene expression and protein synthesis in nerve cells. Rejuvenation Res. 2011. doi:10.1089/rej.2011.1172
- Khavinson VKh, et al. Peptide regulation of gene expression in Alzheimer models. Molecules. 2020;26(1):159. doi:10.3390/molecules26010159
- Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125–133. doi:10.7326/M15-2175
- Rahman S, et al. Recovery peptides in orthopaedic practice. JAAOS Glob Res Rev. 2026. doi:10.5435/JAAOSGlobal-D-25-00236
